Mankind Pharma was listed on the BSE on May 9, 2023. In just 2 years, its stock has given a massive return of more than 70% to its investors. Will Mankind Pharma continue to provide such great returns in the future as well? Let’s explore Mankind Pharma’s growth potential and the Mankind Pharma share price target 2025 to 2050 in this article.
About Mankind Pharma
Mankind Pharma was founded in 1995 by R.C. Juneja. It is known for its high-quality and low-cost medicines. Mankind Pharma offers a wide range of products, such as prescription drugs, over-the-counter (OTC) medicines, diagnostics, and wellness solutions. These products cover a wide range of therapeutic areas, such as dermatology, cardiology, gastroenterology, and anti-infectives. The company is also known for its well-known consumer health brands, such as Gas-O-Fast, Prega News (pregnancy test kits), and Manforce (condoms).
Mankind Pharma Business Model
- Pharmaceutical Manufacturing Business: Mankind Pharma develops, manufactures, and markets a wide range of pharmaceutical formulations across therapeutic areas like antibiotics, gastrointestinal, cardiovascular, dermatology, and anti-diabetic segments. The company operates in both prescription and over-the-counter (OTC) drug categories and produces high-volume generics at affordable prices.
- Consumer Healthcare Business: In addition to prescription medicines, Mankind has a strong presence in the consumer healthcare segment. It owns popular OTC brands such as Manforce (condoms), Prega News (pregnancy detection kits), Unwanted-72 (emergency contraceptive), and Gas-O-Fast (digestive aid). These products contribute significantly to its revenue and brand visibility, especially in Tier II and Tier III cities.
Mankind Pharma Fundamental Analysis
| Stock Name | Mankind Pharma Ltd. |
|---|---|
| NSE Symbol | MANKIND |
| Market Cap | ₹ 97,201 Cr. |
| 52W High | ₹ 3055 |
| 52W Low | ₹ 1901 |
| Stock P/E | 48.9 |
| Book Value | ₹ 347 |
| Dividend Yield | 0.00 % |
| ROCE | 17.9 % |
| ROE | 16.8 % |
| Face Value | ₹ 1.00 |
| Industry PE | 33.4 |
| Price to book value | 6.82 |
| Debt to equity | 0.59 |
| PEG Ratio | 3.32 |
| Quick ratio | 0.86 |
| Shareholders | March 2024 | March 2025 |
|---|---|---|
| Promoters | 74.88% | 72.70% |
| FIIs | 9.87% | 12.92% |
| DIIs | 11.14% | 11.47% |
| Public | 4.10% | 2.89% |
| No. of Shareholders | 1,35,116 | 1,80,597 |
Key Factors Driving Mankind Pharma’s Future Growth
- Expanding Portfolio in Chronic and Lifestyle Diseases: The company is continually expanding its presence in high-growth therapeutic segments, including anti-diabetic, cardiovascular, dermatology, and respiratory care. With India witnessing a sharp rise in lifestyle-related diseases, this diversification ensures long-term revenue growth and higher margins.
- Aggressive Expansion in the Domestic and International Markets: Mankind Pharma is expanding its footprint beyond India, targeting regulated markets such as the U.S. and emerging markets in Asia and Africa.
- Focus on R&D and Complex Generics: Mankind Pharma is increasing its investment in research and development. The company is working on complex generics, injectables, and specialty products, which offer higher margins and limited competition, which will enhance its future profitability.
- Over-The-Counter (OTC) Brand Strength and Consumer Health Push: Well-known OTC brands like Manforce, Prega News, and Gas-O-Fast have made Mankind Pharma a strong consumer healthcare player. The company is actively expanding its OTC and wellness product lines, tapping into India’s growing self-care and preventive healthcare trends.
- Strategic Acquisitions and Partnerships: The company is actively pursuing inorganic growth through acquisitions and partnerships to strengthen its portfolio and enter new segments. Such strategic moves enhance its competitiveness and support future scalability.
Pros of Mankind Pharma
- High Return on Capital Employed (ROCE): Mankind Pharma’s 5yrs average ROCE is 27.0%, which shows that the company is utilizing its capital effectively to generate profits.
- High Return on Equity (ROE): Mankind Pharma’s 5-year average is 20.9%, which shows that the company is using its shareholders’ funds well to generate profits.
- High Promoter Holding: Mankind Pharma has a strong promoter holding of 72.7%, which shows the high confidence of promoters in the company’s future growth and stability.
- Increase in DIIs Holding: DIIs increased their holdings from 11.05% in December 2024 to 11.47% in March 2025, showing a positive outlook towards Mankind Pharma by the DIIs.
Cons of Mankind Pharma
- Overvaluation Concern: Mankind Pharma stock is trading at a PE ratio of 48.9 and a (P/B) ratio of 6.82, which shows that its stock is significantly overvalued compared to its earnings and assets.
- Decrease in FIIs Holding: Foreign Institutional Investors (FIIs) have reduced their holding to 12.92% in March 2025 from 13.34% in December 2024, indicating a decline in FII’s confidence in the company’s future growth prospects.
Mankind Pharma Ltd Balance Sheet
| Particulars | March 2023 | March 2024 | March 2025 |
|---|---|---|---|
| Equity Capital | 40 | 40 | 41 |
| Reserves | 7,395 | 9,323 | 14,291 |
| Borrowings | 170 | 207 | 8,511 |
| Other Liabilities | 2,080 | 2,313 | 4,916 |
| Total Liabilities | 9,686 | 11,883 | 27,760 |
| Fixed Assets | 4,251 | 4,545 | 19,524 |
| CWIP | 550 | 282 | 306 |
| Investments | 1,346 | 2,568 | 2,042 |
| Other Assets | 3,538 | 4,488 | 5,887 |
| Total Assets | 9,686 | 11,883 | 27,760 |
By the end of 2025, the Mankind Pharma share price is expected to be around ₹2950 in normal conditions. In a bear market, it might be ₹2120, and in a bull market, it may go up to ₹3650.
| Mankind Pharma Share Price Target 2025 | Rupees (₹) |
|---|---|
| Bear Market | 2120 |
| Normal Market | 2950 |
| Bull Market | 3650 |
In 2026, the Mankind Pharma share price is expected to be around ₹3530 in a normal situation. In a bear market, it might be ₹2330, and in a bull market, it may cross ₹4750.
| Mankind Pharma Share Price Target 2026 | Rupees (₹) |
|---|---|
| Bear Market | 2330 |
| Normal Market | 3530 |
| Bull Market | 4750 |
According to our analysis, the Mankind Pharma share price is expected to be around ₹4240 in 2027. In a bear market, it might be ₹2560, and in a bull market, it may cross ₹6170.
| Mankind Pharma Share Price Target 2027 | Rupees (₹) |
|---|---|
| Bear Market | 2560 |
| Normal Market | 4240 |
| Bull Market | 6170 |
According to our analysis, the Mankind Pharma share price may trade near ₹5100 by 2028; bearish conditions could pull it down to ₹2820, while a strong bull run might lift it to ₹8000.
| Mankind Pharma Share Price Target 2028 | Rupees (₹) |
|---|---|
| Bear Market | 2820 |
| Normal Market | 5100 |
| Bull Market | 8000 |
Under normal conditions, the Mankind Pharma share price might hit ₹6100 by 2029. A bearish trend could lower it to ₹3100, whereas a bullish surge could raise it to ₹10,500.
| Mankind Pharma Share Price Target 2029 | Rupees (₹) |
|---|---|
| Bear Market | 3100 |
| Normal Market | 6100 |
| Bull Market | 10,500 |
In a normal situation, the Mankind Pharma share price is projected to be approximately ₹7300 in 2030. In a bear market, the value may be as low as ₹3400, while in a bull market, it may rise to ₹13,550.
| Mankind Pharma Share Price Target 2030 | Rupees (₹) |
|---|---|
| Bear Market | 3400 |
| Normal Market | 7300 |
| Bull Market | 13,500 |
By 2035, the Mankind Pharma share price is projected to be around ₹14,600 under normal conditions. In adverse markets, the price could fall to ₹5100, while favorable conditions might push it up to ₹40,600.
| Mankind Pharma Share Price Target 2035 | Rupees (₹) |
|---|---|
| Bear Market | 5100 |
| Normal Market | 14,600 |
| Bull Market | 40,600 |
Under normal conditions, the Mankind Pharma share price might hit ₹29,200 by 2040. A bearish trend could lower it to ₹7600, whereas a bullish surge could raise it to ₹1,22,000.
| Mankind Pharma Share Price Target 2040 | Rupees (₹) |
|---|---|
| Bear Market | 7600 |
| Normal Market | 29,000 |
| Bull Market | 1,22,000 |
In 2050, the Mankind Pharma share price is expected to be around ₹1,16,800 in a normal situation. In a bear market, it might be ₹23,000, and in a bull market, it may go up to ₹7,31,700.
| Mankind Pharma Share Price Target 2050 | Rupees (₹) |
|---|---|
| Bear Market | 23,000 |
| Normal Market | 1,16,800 |
| Bull Market | 7,31,700 |
| Years | Target Price |
|---|---|
| Mankind Pharma Share Price Target 2025 | ₹2120 to ₹3650 |
| Mankind Pharma Share Price Target 2026 | ₹2330 to ₹4750 |
| Mankind Pharma Share Price Target 2027 | ₹2560 to ₹6170 |
| Mankind Pharma Share Price Target 2028 | ₹2820 to ₹8000 |
| Mankind Pharma Share Price Target 2029 | ₹3100 to ₹10,500 |
| Mankind Pharma Share Price Target 2030 | ₹3400 to ₹13,550 |
| Mankind Pharma Share Price Target 2035 | ₹5100 to ₹40,600 |
| Mankind Pharma Share Price Target 2040 | ₹7600 to ₹1,22,000 |
| Mankind Pharma Share Price Target 2050 | ₹23,000 to ₹7,31,700 |
Disclaimer
This article is for educational purposes only. It is not a stock recommendation and should not be treated as such. Please ask your financial advisor before making any investment decision.
Also Read: JSW Steel Share Price Target 2025 to 2050
